Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen

Clinical Endocrinology

Volumn 83, Issue 5, 2015, Pages 607-615

  Meriggiola, Maria Cristina ^a   Gava, Giulia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GONADORELIN AGONIST; SPIRONOLACTONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR MORTALITY; DRUG SAFETY; ESTROGEN THERAPY; GENDER DYSPHORIA; HORMONAL THERAPY; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MALE; MALE TO FEMALE TRANSGENDER; MENINGIOMA; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PRIORITY JOURNAL; PROLACTINOMA; PROSTATE CANCER; REPRODUCTION; SEXUAL FUNCTION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; FEMALE; FEMINIZATION; FERTILITY PRESERVATION;

ANDROGEN ANTAGONISTS; ESTROGENS; FEMALE; FEMINIZATION; FERTILITY PRESERVATION; GENDER DYSPHORIA; HUMANS; MALE;

EID: 84955504371     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12754     Document Type: Article

References (73)

1. Gorin-Lazard, A., Baumstarck, K., Boyer, L., et al,. (2012) Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. The Journal of Sexual Medicine, 9, 531-541.
2. Gõmez-Gil, E., Zubiaurre-Elorza, L., de Antonio, I.E., et al,. (2014) Determinants of quality of life in Spanish transsexuals attending a gender unit before genital sex reassignment surgery. Quality of Life Research, 23, 669-676.
3. Spack, N.P., Edwards-Leeper, L., Feldman, H.A., et al,. (2012) Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics, 129, 418-425.
4. De Vries, A.L., Kreukels, B.P., Steensma, T.D., et al,. (2011) Comparing adult and adolescent transsexuals: an MMPI-2 and MMPI-A study. Psychical Research, 186, 414-418.
5. Baba, T., Endo, T., Ikeda, K., et al,. (2011) Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in Japan. The Journal of Sexual Medicine, 8, 1686-1693.
6. Kruijver, F.P., Zhou, J.N., Pool, C.W., et al,. (2000) Male-to-female transsexuals have female neuron numbers in a limbic nucleus. Journal of Clinical Endocrinology and Metabolism, 85, 2034-2041.
7. Hare, L., Bernard, P., Sánchez, F.J., et al,. (2009) Androgen receptor repeat length polymorphism associated with male-to-female transsexualism. Biological Psychiatry, 65, 93-96.
8. Olson, J., Forbes, C., &, Belzer, M., (2011) Management of the transgender adolescent. Archives of Pediatrics and Adolescent Medicine, 165, 171-176.
9. Hembree, W.C., Cohen-Kettenis, P., Delemarre-van de Waal, H.A., et al,. (2009) Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice guideline. Journal of Clinical Endocrinology and Metabolism, 94, 3132-3154.
10. Menvielle, E., &, Gomez-Lobo, V., (2011) Management of children and adolescents with gender dysphoria. Journal of Pediatric and Adolescent Gynecology, 24, 183-188.
11. Toorians, A.W., Thomassen, M.C., Zweegman, S., et al,. (2003) Venous thrombosis and changes of hemostatic variables during crosssex hormone treatment in transsexual people. Journal of Clinical Endocrinology and Metabolism, 88, 5723-5729.
12. Asscheman, H., Giltay, E.J., Megens, J.A., et al,. (2011) A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 164, 635-642.
13. Stadel, B.V., Sternthal, P.M., Schlesselman, J.J., et al,. (1980) Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertility and Sterility, 33, 257-260.
14. Goldzieher, J.W., Dozier, T.S., &, de la Pena, A., (1980) Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. I. Ethynylestradiol. Contraception, 21, 1-16.
15. Meriggiola, M.C., Jannini, E.A., Lenzi, A., et al,. (2010) Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. European Journal of Endocrinology, 162, 831-833.
16. Murad, M.H., Elamin, M.B., Garcia, M.Z., et al,. (2010) Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clinical Endocrinology (Oxford), 72, 214-231.
17. Knezevich, E.L., Viereck, L.K., &, Drincic, A.T., (2012) Medical management of adult transsexual persons. Pharmacotherapy, 32, 54-66.
18. Asscheman, H., T'Sjoen, G., Lemaire, A., et al,. (2014) Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia, 46, 791-795.
19. Wierckx, K., Van Caenegem, E., Schreiner, T., et al,. (2014) Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European Network for the Investigation of Gender Incongruence. The Journal of Sexual Medicine, 11, 1999-2011.
20. Seal, L.J., Franklin, S., Richards, C., et al,. (2012) Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. Journal of Clinical Endocrinology and Metabolism, 97, 4422-4428.
21. Savidou, I., Deutsch, M., Soultati, A.S., et al,. (2006) Hepatotoxicity induced by cyproterone acetate: a report of three cases. World Journal of Gastroenterology, 12, 7551-7555.
22. Gil, M., Oliva, B., Timoner, J., et al,. (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. British Journal of Clinical Pharmacology, 72, 965-968.
23. Moore, E., Wisniewski, A., &, Dobs, A., (2003) Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism, 88, 3467-3473.
24. Tangpricha, V., Ducharme, S.H., Barber, T.W., et al,. (2003) Endocrinologic treatment of gender identity disorders. Endocrine Practice, 9, 12-21.
25. Gulmez, S.E., Lassen, A.T., Aalykke, C., et al,. (2008) Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. British Journal of Clinical Pharmacology, 66, 294-299.
26. Dahl, M., Feldman, J.L., Goldberg, J., et al,. (2006) Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines. Transgender Health Program, Vancouver, BC, 2006. Available from: http://transhealth.vch.ca/ (accessed 1 September 2014).
27. Spack, N.P., (2013) Management of transgenderism. JAMA, 309, 478-484.
28. Mueller, A., &, Gooren, L., (2008) Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 159, 197-202.
29. Gooren, L.J., Giltay, E.J., &, Bunck, M.C., (2008) Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. Journal of Clinical Endocrinology and Metabolism, 93, 19-25.
30. Rossouw, J.E., Anderson, G.L., Prentice, R.L., et al,. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288, 321-333.
31. Giltay, E.J., &, Gooren, L.J., (2000) Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology and Metabolism, 85, 2913-2921.
32. McNeill, E.J., (2006) Management of the transgender voice. Journal of Laryngology and Otology, 120, 521-523.
33. Gooren, L.J., (2011) Clinical practice. Care of transsexual persons. New England Journal of Medicine, 364, 1251-1257.
34. Gooren, L.J., &, Giltay, E.J., (2014) Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. Andrologia, 46, 570-575.
35. Ettner, R., (2013) Care of the elderly transgender patient. Current opinion in Endocrinology, Diabetes, and Obesity, 20, 580-584.
36. Sapino, A., Pagani, A., Godano, A., et al,. (1987) Effects of estrogens on the testis of transsexuals: a pathological and immunocytochemical study. Virchows Arch A Pathological Anatomy and Histopathology, 411, 409-414.
37. Thiagaraj, D., Gunasegaram, R., Loganath, A., et al,. (1987) Histopathology of the testes from male transsexuals on oestrogen therapy. Annals of the Academy of Medicine, Singapore, 16, 347-348.
38. Lübbert, H., Leo-Rossberg, I., &, Hammerstein, J., (1992) Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male. Fertility and Sterility, 58, 603-608.
39. Wierckx, K., Stuyver, I., Weyers, S., et al,. (2012) Sperm freezing in transsexual women. Archives of Sexual Behavior, 41, 1069-1071.
40. Van Kesteren, P., Lips, P., Gooren, L.J., et al,. (1998) Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clinical Endocrinology (Oxford), 48, 347-354.
41. Ruetsche, A.G., Kneubuehl, R., Birkhaeuser, M.H., et al,. (2005) Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporosis International, 16, 791-798.
42. Mueller, A., Zollver, H., Kronawitter, D., et al,. (2011) Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Experimental and Clinical Endocrinology & Diabetes, 119, 95-100.
43. Lapauw, B., Taes, Y., Simoens, S., et al,. (2008) Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone, 43, 1016-1021.
44. T'Sjoen, G., Weyers, S., Taes, Y., et al,. (2009) Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. Journal of Clinical Densitometry, 12, 306-313.
45. Van Caenegem, E., Taes, Y., Wierckx, K., et al,. (2013) Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone, 54, 92-97.
46. Klein, C., &, Gorzalka, B.B., (2009) Sexual functioning in transsexuals following hormone therapy and genital surgery: a review. The Journal of Sexual Medicine, 6, 2922-2939.
47. Weyers, S., Elaut, E., De Sutter, P., et al,. (2009) Long-term assessment of the physical, mental, and sexual health among transsexual women. The Journal of Sexual Medicine, 6, 752-760.
48. Elaut, E., De Cuypere, G., De Sutter, P., et al,. (2008) Hypoactive sexual desire in transsexual women: prevalence and association with testosterone levels. European Journal of Endocrinology, 158, 393-399.
49. Wierckx, K., Elaut, E., Declercq, E., et al,. (2013) Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. European Journal of Endocrinology, 169, 471-478.
50. Wierckx, K., Mueller, S., Weyers, S., et al,. (2012) Long-term evaluation of cross-sex hormone treatment in transsexual persons. The Journal of Sexual Medicine, 9, 2641-2651.
51. Meriggiola, M.C., &, Berra, M., (2012) Long-term cross-sex hormone treatment is safe in transsexual subjects. Asian Journal of Andrology, 14, 813-814.
52. Ott, J., Kaufmann, U., Bentz, E.K., et al,. (2010) Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertility and Sterility, 93, 1267-1272.
53. Renoux, C., Dell'Aniello, S., &, Suissa, S., (2010) Hormone replacement therapy and the risk of venous thromboembolism: population-based study. Journal of Thrombosis and Haemostasis, 8, 979-986.
54. Van Kesteren, P.J., Asscheman, H., Megens, J.A., et al,. (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology (Oxford), 47, 337-342.
55. Gooren, L.J., Van Trotsenburg, M.A., Giltay, E.J., et al,. (2013) Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. The Journal of Sexual Medicine, 10, 3129-3134.
56. Johansen Taber, K.A., Morisy, L.R., Osbahr, A.J., et al,. (2010) Male breast cancer: risk factors, diagnosis, and management (Review). Oncology Reports, 24, 1115-1120.
57. Smith, R.A., Cokkinides, V., &, Eyre, H.J., (2010) American Cancer Society guidelines for the early detection of cancer, 2006. CA: A Cancer Journal for Clinicians, 56, 11-25 quiz 49-50.
58. Van Kesteren, P., Meinhardt, W., van der Valk, P., et al,. (1996) Effects of estrogens only on the prostates of aging men. Journal of Urology, 156, 1349-1353.
59. Casella, R., Bubendorf, L., Schaefer, D.J., et al,. (2005) Does the prostate really need androgens to grow? Transurethral resection of the prostate in a male-to-female transsexual 25 years after sex-changing operation. Urologia Internationalis, 75, 288-290.
60. Gooren, L., &, Morgentaler, A., (2013) Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia, 46, 1156-1160.
61. Van Haarst, E.P., Newling, D.W., Gooren, L.J., et al,. (1998) Metastatic prostatic carcinoma in a male-to-female transsexual. British Journal of Urology, 81, 776.
62. Dorff, T.B., Shazer, R.L., Nepomuceno, E.M., et al,. (2007) Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clinical Genitourinary Cancer, 5, 344-346.
63. Thurston, A.V., (1994) Carcinoma of the prostate in a transsexual. British Journal of Urology, 73, 217.
64. Bunck, M.C., Debono, M., Giltay, E.J., et al,. (2009) Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Reports, 2009, bcr02.
65. Cunha, F.S., Domenice, S., Câmara, V.L., et al,. (2014) Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia, 47, 680-684.
66. Gazzeri, R., Galarza, M., &, Gazzeri, G., (2007) Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. New England Journal of Medicine, 357, 2411-2412.
67. Bergoglio, M.T., Gõmez-Balaguer, M., Almonacid Folch, E., et al,. (2013) Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinology Nutrition, 60, 264-267.
68. Deipolyi, A.R., Han, S.J., &, Parsa, A.T., (2010) Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. Journal of Clinical Neuroscience, 17, 1324-1326.
69. Weyers, S., Decaestecker, K., Verstraelen, H., et al,. (2009) Clinical and transvaginal sonographic evaluation of the prostate in transsexual women. Urology, 74, 191-196.
70. Weyers, S., De Sutter, P., Hoebeke, S., et al,. (2010) Gynaecological aspects of the treatment and follow-up of transsexual men and women. Facts Views and Vision in ObGyn, 2, 35-54.
71. Lips, P., Asscheman, H., Uitewaal, P., et al,. (1989) The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. Journal of Bone and Mineral Research, 4, 657-662.
72. Reutrakul, S., Ongphiphadhanakul, B., Piaseu, N., et al,. (1998) The effects of oestrogen exposure on bone mass in male to female transsexuals. Clinical Endocrinology (Oxford), 49, 811-814.
73. Haraldsen, I.R., Haug, E., Falch, J., et al,. (2007) Cross-sex pattern of bone mineral density in early onset gender identity disorder. Hormones and Behavior, 52, 334-343.